3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Heart -

Early close of trial of treatment for peripheral arterial disease announced

HeartOct 02, 05

Vasogen Inc. (VSGN), focused on the development of immune modulation therapies for the treatment of cardiovascular disease, announced the early close out of the 550-patient, double-blind, placebo-controlled Phase 3 SIMPADICO trial of its Celacade technology for the treatment of symptomatic peripheral arterial disease (PAD).

The decision to close out the trial at this time is based on a recommendation received from the SIMPADICO Steering Committee.

The Steering Committee’s recommendation was based on a recommendation by the trial’s External Safety and Efficacy Monitoring Committee (ESEMC). The ESEMC recommended the early close out of the study based on the absence of a sufficiently strong efficacy signal and their observation of a modest imbalance in the distribution of a small number of malignancy cases.

Based on the steering committee’s own review and the findings of an independent expert in medical oncology, the steering committee concluded that no safety concern existed. However, given that the ESEMC’s analysis also incorporated efficacy information and all patients have completed the assessments necessary for the analysis of the primary endpoint, the steering committee recommended the early close out of the trial.

The SIMPADICO trial enrolled 553 patients with moderate to severe PAD at 50 centers throughout North America. The study population was predominantly male (72%), Caucasian (89%), current or ex-smokers (91%), with a mean age of 67 years. The primary endpoint in SIMPADICO is the change in maximal walking distance after 6 months’ treatment; a primary efficacy endpoint recognized by the U.S. Food and Drug Administration (FDA) and other regulatory authorities for approving new treatments for symptomatic PAD.

Clinical assessments of the 6-month primary endpoint were completed in July of this year and the majority of patients in the study have completed an additional 6 months of therapy as outlined in the study protocol.

Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease.

2005, NewsRx.com.

Print Version
comments powered by Disqus

  New superfoods could help key protein keep bodies healthy
  Mobile app on emergency cardiac care aids best decisions in seconds
  Train your heart to protect your mind
  Mass. General study identifies path to safer drugs for heart disease, cancer
  Tweaking MRI to track creatine may spot heart problems earlier, Penn Medicine study suggests
  Method to estimate LDL-C may provide more accurate risk classification
  Texting heart medication reminders improved patient adherence
  Hybrid heart valve is strong, durable in early tests
  Cardiopoietic ‘Smart’ Stem Cells Show Promise in Heart Failure Patients
  Vitamin D deficiency ups heart disease risk
  Heart surgery safe in Jehovah’s Witnesses
  Magnet helps target transplanted iron-loaded cells to key areas of heart


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site